AstraZeneca (LON:AZN) Given "Overweight" Rating at JPMorgan Chase & Co.

JPMorgan Chase & Co. reaffirmed their overweight rating on shares of AstraZeneca (LON:AZN - Free Report) in a research report report published on Friday morning, Marketbeat.com reports. JPMorgan Chase & Co. currently has a £140 ($175.50) price target on the biopharmaceutical company's stock.

A number of other analysts also recently weighed in on the stock. Shore Capital reaffirmed a "buy" rating on shares of AstraZeneca in a report on Thursday, November 7th. Berenberg Bank reiterated a "buy" rating and set a £150 ($188.04) price objective on shares of AstraZeneca in a research report on Monday, September 2nd. Finally, Deutsche Bank Aktiengesellschaft reissued a "hold" rating and set a £110 ($137.90) price objective on shares of AstraZeneca in a report on Tuesday, September 3rd. One investment analyst has rated the stock with a sell rating, two have given a hold rating and six have assigned a buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of £104.12 ($130.53).

AstraZeneca Stock Performance

Shares of LON:AZN traded up GBX 412 ($5.16) on Friday, reaching £104.74 ($131.30). 2,847,260 shares of the company's stock were exchanged, compared to its average volume of 3,932,934. The company has a current ratio of 0.89, a quick ratio of 0.59 and a debt-to-equity ratio of 84.97. AstraZeneca has a twelve month low of GBX 9,461 ($118.60) and a twelve month high of £133.88 ($167.83). The company has a fifty day moving average of £113.96 and a 200-day moving average of £120.77. The company has a market capitalization of £162.35 billion, a price-to-earnings ratio of 3,239.37, a PEG ratio of 0.86 and a beta of 0.17.

Insider Buying and Selling

In related news, insider Pascal Soriot purchased 20,000 shares of the firm's stock in a transaction on Thursday, November 14th. The shares were acquired at an average cost of £102.03 ($127.91) per share, with a total value of £2,040,600 ($2,558,104.55). Also, insider Tony Mok bought 1,500 shares of the firm's stock in a transaction that occurred on Tuesday, November 19th. The stock was purchased at an average cost of £126.80 ($158.96) per share, for a total transaction of £190,200 ($238,435.50). In the last quarter, insiders have purchased 23,500 shares of company stock valued at $223,316,000. Corporate insiders own 0.04% of the company's stock.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.